The production process of CAR-T products is complicated and time-consuming, and the preparation failure rate is as high as 14%. The failed product preparation is fatal to tumor patients. The initial blood cell samples of patients with autologous CAR-T therapy are very different and uneven. How can we maintain stable and high-quality cell preparation and production? How can we ensure that enough CAR-T cell products are produced in the shortest time for the patient's reinfusion therapy?
June 4th: Causes of CAR-T product preparation failure and countermeasures
2020-06-04 All day